Track Abbott India Ltd.'s current share price, historical price chart, 52-week high/low, and performance across different time periods.
1 Week returns: 2.72 %
Low
25,524.7
High
27,671.4
1 Month returns: 1.80 %
Low
25,195.0
High
27,671.4
1 Year returns: -23.17 %
Low
25,150.0
High
35,310.0
3 Year CAGR: 3.75 %
Low
22,000.0
High
37,000.0
5 Year CAGR: 8.81 %
Low
15,514.0
High
37,000.0
Note: Prices may be delayed by a few minutes. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
Multi-year trends for Abbott India Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.
Abbott India Ltd. Shareholding Pattern
Quarterly breakdown of Abbott India Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.
Bulk, Block and Insider Trades
Recent bulk deals, block deals, and insider trading activity in Abbott India Ltd. shares as reported to NSE and BSE.
Frequently Asked Questions
What is the current share price of Abbott India Ltd.?
The current share price of Abbott India Ltd. is ₹ 26,245.00 as of 8 Jul 2026.
What is the market capitalisation of Abbott India Ltd.?
The market capitalisation of Abbott India Ltd. stands at ₹ 55,768.00 Cr.
What is the PE ratio of Abbott India Ltd.?
The Price-to-Earnings (PE) ratio of Abbott India Ltd. is 35.93 as of the latest trailing twelve months data.
What is the ROE and ROCE of Abbott India Ltd.?
Abbott India Ltd. has a Return on Equity (ROE) of 34.46% and a Return on Capital Employed (ROCE) of 38.74% as per the latest financial reports.
What is the 52-week high and low of Abbott India Ltd.?
The 52-week high of Abbott India Ltd. is - and the 52-week low is -.
What is the dividend yield of Abbott India Ltd.?
The dividend yield of Abbott India Ltd. is 1.81% based on the current market price.
What is the FII and DII holding in Abbott India Ltd.?
Foreign Institutional Investors (FII) hold 0.27%, Domestic Institutional Investors (DII) hold 8.74% and retail/public investors hold 15.10% of Abbott India Ltd. shares.
What sector does Abbott India Ltd. belong to?
Abbott India Ltd. operates in the Healthcare sector. 85.71% of analysts have a Buy or Strong Buy rating on Abbott India Ltd. with a consensus target price of ₹ 32,400.00, implying 23.45% upside from current levels.
What is the beta of Abbott India Ltd.?
The beta of Abbott India Ltd. is 0.36, indicating its price volatility relative to the broader market. Over the past 1 year, Abbott India Ltd. has delivered an absolute return of -25.65%.
What is the RSI of Abbott India Ltd.?
The 14-day Relative Strength Index (RSI) of Abbott India Ltd. is 51.28, placing it in the neutral zone. An RSI above 70 is considered overbought and below 30 is considered oversold.
Net Revenue FY
Profit After Tax FY
ROE FY
EBITDA FY
Holdings and Presence
Indices and prominent investors with a stake in this stock.
Overview of Abbott India Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.
Abbott India Limited is an India-based pharmaceutical company. The Company is involved in product development, manufacturing, sales, and customer service. It distributes products and solutions in multiple therapeutic categories, such as womens health, gastroenterology, cardiology, metabolic disorders and primary care. It operates in a single reportable business segment, which is Pharmaceuticals. The Company’s products include Arachitol Nano, Digeraft, Influvac, Colospa, Duphalac, Librax, Creon, Duphaston, Prothiaden, Cremaffin, Duvadilan, Thyronorm, Cremaffin Plus, Ganaton, Udiliv, Digene, Heptral, Vertin, Zolfresh, Citrosoda UTI, Digene Insta On The Go, Digeraft tablet, Duphaston OD, Pneumoshield 14, Prothiaden Neu, Vonefi, Levesam, and LOBATE M Skin Cream, among others. The Company sells its products through independent distributors primarily within India.
Abbott India Limited is an India-based pharmaceutical company. The Company is involved in product development, manufacturing, sales, and customer service. It distributes products and solutions in multiple therapeutic categories, such as womens health, gastroenterology, cardiology, metabolic disorder...
Key personnel
Ms. Maithilee Mistry
Chief Financial Officer
Ms. Sangeeta Mukesh Shetty
Compliance Officer, Company Secretary, Associate Director - Secretarial
Mr. Rajan Kalantre
Director - Business Human Resources
Dr. Jejoe Karankumar
Director - Medical Affairs
Ms. Anushree Kunhambu
Associate Director - New Product Introduction and Therapy Area Strategy
Mr. Amol Metkar
Plant Director, Goa
Ms. Richa Tripathi
Associate Director - Sales Force Effectiveness, Project Management Office
15-16 floors, Godrej BKC,Plot C-68 G Block, Bandra-Kurla Complex, Near MCA Club, , 400051, India
Mar 2020
Jun 2020
Sep 2020
Dec 2020
Mar 2021
Jun 2021
Sep 2021
Dec 2021
Mar 2022
Jun 2022
Sep 2022
Dec 2022
Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Promoter
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
Indian Promoter
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Foreign Promoter
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
74.99
Institutions
7.72
7.32
7.49
6.92
6.54
6.99
7.12
6.98
7.74
8.15
8.05
8.59
8.81
8.97
9.01
8.92
9.09
8.99
9.16
9.17
9.08
9.35
9.27
9.18
9.19
Mutual Funds / UTI
4.79
4.99
4.65
4.00
3.22
3.42
3.64
3.53
4.31
4.84
5.67
6.41
6.88
7.27
7.32
7.26
7.57
7.59
7.69
7.77
7.73
7.77
7.78
7.65
7.68
FI/Bank/Insurance
0.51
0.25
0.35
0.51
1.39
2.38
0.66
0.66
0.64
0.40
2.06
1.86
1.61
1.40
1.39
1.35
1.23
1.12
1.22
1.15
1.10
1.15
1.07
1.08
1.06
Govt
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
FII
1.64
1.34
1.15
1.10
1.01
0.25
0.24
0.22
0.22
0.20
0.20
0.20
0.19
0.19
0.19
0.18
0.18
0.18
0.17
0.17
0.16
0.16
0.16
0.19
0.27
Other Institutions
0.77
0.74
1.34
1.31
0.93
0.93
2.59
2.56
2.56
2.70
0.12
0.11
0.12
0.10
0.12
0.12
0.11
0.10
0.09
0.09
0.08
0.26
0.26
0.27
0.19
Non-Institution
17.30
17.69
17.52
18.09
18.47
18.03
17.89
18.04
17.27
16.86
16.95
16.42
16.21
16.05
16.00
16.09
15.92
16.02
15.85
15.84
15.93
15.66
15.75
15.83
15.81
Bodies Corporate
1.17
-
-
-
-
-
-
-
-
-
0.73
0.74
0.72
0.69
0.67
0.67
0.66
0.67
0.66
0.67
0.69
0.72
0.70
0.71
0.71
Others (incl. Retail)
No. of shareholders
16.13
48,337
17.69
63,919
17.52
68,703
18.09
76,203
18.47
84,398
18.03
75,470
17.89
73,349
18.04
83,172
17.27
90,423
16.86
82,045
16.22
82,234
15.68
73,666
15.49
70,854
15.36
68,423
15.33
67,792
15.42
71,207
15.26
68,370
15.35
70,575
15.19
68,497
15.17
66,950
15.24
68,871
14.94
66,580
15.05
70,216
15.12
74,773
15.10
74,932
Stock Analysis
Fundamental analysis overview of Abbott India Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.
Views
Red Flags
Positive
High and stable ROE
The company reported strong ROE of 34.46% for 12-month ended 31 Mar 2026 and ROE declined marginally by -120 bps from 1 year ago
What is ROE (FY)?
High and stable operating margin
The company reported strong operating margin of 26.21% for 12-month ended 31 Mar 2026 and operating margin improved marginally by 88 bps from 1 year ago
What is Operating profit margin?
Low Debt to Equity, not much change from last year
The company has low Debt to Equity of 0.04 as on 31 Mar 2026 and Debt to Equity decreased marginally by 0.01 in the last 1 year
What is Debt to Equity?
Consistently pays dividend
The company has not missed dividend payments once in the last 10 financial years
What is Dividend streak?
Company is net cash
The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet
What is Net Debt ?
Negative
Expensive and at a premium to industry median P/E
PE TTM of 35.93 indicates that the stock is expensive on a standalone basis and is at a 18.31% premium to industry median P/E
What is P/E Ratio?
Median: 30.37
Value 35.93
-215.443255.34
Analysts have been downgrading forward EPS estimates
Analyst EPS estimate (consensus) for forward EPS has decreased by -1.28% in the last 3 months, indicating weak earnings momentum
What is Earnings upgrade (3M)?
Low revenue growth and lower than median growth of industry
The company delivered moderate revenue growth of 8.11% for 12-month ended 31 Mar 2026 and the growth was 3.13 percentage points lower than median growth of industry
What is Sales growth (1Y)?
Median: 11.24
Value 8.11
-82.35114662
Low EPS growth and in line with median growth of industry
The company delivered low EPS growth of 9.72% for 12-month ended 31 Mar 2026 and the growth was 1.6 percentage points higher than median growth of industry
What is EPS growth (1Y)?
Neutral
Company's earnings are of moderate quality
Earnings quality score of 60.5 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion
What is Earnings quality score?
60.5 / 100
Moderate dividend yield
The company has a moderate dividend yield of 1.81%
What is Dividend yield?
No red flags found!
No significant red flags found in the stock.
No bulk, block or insider trade data available.
Corporate Actions
History of Abbott India Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.